Form 4 · Filed May 20, 2026, 08:18 PM UTC
ELVN/Enliven Therapeutics, Inc.
Collins Helen Louise — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
5 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026 | M | other | 5,000 | $2 | $12,400 | 30,000 |
| May 18, 2026 | S | sell | 3,475 | $40 | $137,381 | 26,525 |
| May 18, 2026 | S | sell | 1,302 | $40 | $52,402 | 25,223 |
| May 18, 2026 | S | sell | 223 | $41 | $9,189 | 25,000 |
| May 18, 2026 | M | other | 5,000 | — | — | 126,268 |
Source: SEC EDGAR raw filing ↗ · Accession 0001701247-26-000007